Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-25-015459
Filing Date
2025-04-24
Accepted
2025-04-24 16:27:39
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ef20047843_defa14a.htm DEFA14A 12316
2 image00003.jpg GRAPHIC 138135
3 image00004.jpg GRAPHIC 117915
  Complete submission text file 0001140361-25-015459.txt   366185
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 25867719
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)